Healthcare
Procaps Group S.A.(PROCF)
Live Price
Offline$0.0251
+0.00% today
1Y Change
-98.28%
Window
Jun 23, 2025 → Jun 10, 2026
- Market Cap
- $100.00M
- Revenue Growth
- +5.1%
- EPS Growth
- +11.1%
- Dividend Yield
- 0.0%
Coverage: 246 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Procaps Group S.A. (PROCF) is a Healthcare stock with a market cap of $100.00M and listed on PNK. The stock last traded around $0.03 and down 98.3% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +5.1%, EPS growth of +11.1%, a dividend yield of 0.0%. What stands out right now is revenue +5.1%, EPS +11.1%, free cash flow +503.0% with operating margin 12.8% and ROIC 12.1%. Valuation is more restrained than many high-expectation growth names at P/E 2.4 and price/sales 0.2. Stock Foundry combines PROCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+5.1% vs +7.6% peer median
Operating Margin
Below sector median
+12.8% vs +19.4% peer median
P/E
Below sector median
2.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +5.1% and EPS at +11.1%, with operating margin around 12.8%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PROCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PROCF Max Drawdown
-99.98%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PROCF and SPY.
Company Overview
Procaps Group S.A.
Other OTC
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
- Leadership
- Melissa Angelini
- IPO Date
- Oct 4, 2021
- Employees
- 5.0k
- Street Address
- 9 Rue de Bitbourg
- Mailing
- Luxembourg City, 1273
- Region
- Luxembourg City, LU
- Reporting Currency
- USD
- Investor Line
- 356 7995 6138
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 2.4
- EV/EBITDA
- 3.6
- Price/Sales
- 0.2
- Price/Book
- —
Growth
- Revenue
- +5.1%
- EPS
- +11.1%
- Free Cash Flow
- +503.0%
Profitability
- Gross Margin
- 58.4%
- Operating Margin
- 12.8%
- Net Margin
- 10.4%
- ROE
- -221.9%
- ROIC
- 12.1%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.81
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.